Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7176145 | 0.83 | SLC6A2 (0.34) | — | |
| SCHEMBL19851617 | 0.82 | ESR1 (0.44) | ESR1 | |
| SCHEMBL502576 | 0.81 | BRS3 (0.31) | — | |
| SCHEMBL22482128 | 0.81 | — | — | |
| SCHEMBL118438 | 0.78 | NUDT1 (0.33) | — | |
| SCHEMBL502258 | 0.78 | — | — | |
| SCHEMBL19401021 | 0.78 | — | — | |
| SCHEMBL13224537 | 0.78 | MEN1 (0.39) | — | |
| SCHEMBL28324088 | 0.77 | — | — | |
| SCHEMBL22916695 | 0.77 | ESR1 (0.33) | ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11859242-B2 | Template-directed nucleic acid targeting compounds | CARNEGIE MELLON UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11859242-B2 | Template-directed nucleic acid targeting compounds | CARNEGIE MELLON UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230399326-A1 | PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399326-A1 | PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | US | disclosed |
| US-11820835-B2 | Cyclic tetrapeptide analogs | UNIVERSITY OF KANSAS (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820835-B2 | Cyclic tetrapeptide analogs | UNIVERSITY OF KANSAS (US) | 2023-11-21 | — | — | US | disclosed |
| US-11814527-B2 | Three-dimensional printing with supramolecular templated hydrogels | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230322732-A1 | RIP1 Inhibitory Compounds and Methods for Making and Using the Same | RIGEL PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230310454-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230303555-A1 | PYRIMID-2-YL-PYRAZOLE COMPOUNDS AS IRAK INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
| US-20080051326-A1 | Antiinfective Lipopeptides | CUBIST PHARMACEUTICALS, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051326-A1 | Antiinfective Lipopeptides | CUBIST PHARMACEUTICALS, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | SCHERING CORPORATION | 2008-02-21 | — | — | US | disclosed |
| US-20070260040-A1 | Amino Acid Surrogates for Peptidic Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070260040-A1 | Amino Acid Surrogates for Peptidic Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBVIE INC. | 2007-07-05 | — | — | US | disclosed |
| US-7202363-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202363-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310454-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | ESR1 3454/4885 |
| US-20230399326-A1 | PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONS | IRAK1, IRAK3, IRAK2 | ESR1 4730/4885 |
| US-20070260040-A1 | Amino Acid Surrogates for Peptidic Constructs | ARGLU1, ARG1, QRFPR | ESR1 1940/4885 |
| US-20230322732-A1 | RIP1 Inhibitory Compounds and Methods for Making and Using the Same | RIPK1, RIPK2, RIPK3 | ESR1 3454/4885 |
| US-20080051326-A1 | Antiinfective Lipopeptides | VIP, NGLY1, PREP | ESR1 4422/4885 |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | CDKL2, CDK2, CDKL1 | ESR1 1494/4885 |
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | ESR1 3826/4885 |
| US-20230303555-A1 | PYRIMID-2-YL-PYRAZOLE COMPOUNDS AS IRAK INHIBITORS | IRAK2, IRAK3, IRAK1 | ESR1 2415/4885 |
| US-11820835-B2 | Cyclic tetrapeptide analogs | CALCA, VIP, OPRL1 | ESR1 4552/4885 |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | GHSR, GHRHR, GIPR | ESR1 534/4885 |
| US-11859242-B2 | Template-directed nucleic acid targeting compounds | TARDBP, HTT, TRDMT1 | ESR1 2426/4885 |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABL1, ERBB2, LCK | ESR1 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.